Treatment of Ischemic Strokes Related to Antiphospholipid Antibody Syndrome with SLE
Diagnostic Considerations
- The European League Against Rheumatism recommends that ischemic stroke/TIA comprises over 80% of cerebrovascular disease cases in SLE patients with APS, while CNS vasculitis is rare 4
- Strong risk factors for stroke in these patients include generalized SLE disease activity and persistently positive moderate-to-high titers of antiphospholipid antibodies, as stated by the Annals of the Rheumatic Diseases 4, 5
- Initial diagnostic workup should include MRI with diffusion-weighted imaging (DWI) to exclude hemorrhage, assess brain injury, and identify the vascular lesion responsible for the ischemic deficit, according to the Annals of the Rheumatic Diseases 1, 4
Treatment Algorithm
Secondary Prevention
- The American College of Cardiology recommends anticoagulation with warfarin (target INR 2.0-3.0) as first-line therapy for patients who meet criteria for APS with thrombotic events 2, 3
- Long-term anticoagulation should be considered in patients with stroke who fulfill the classification criteria for APS to prevent recurrent stroke, as recommended by the European League Against Rheumatism 5
- Anticoagulation is superior to antiplatelet therapy for secondary prevention of arterial events (including stroke/TIA) in APS, according to the Annals of the Rheumatic Diseases 1
Additional Treatment Considerations
- Control of general SLE disease activity is essential alongside anticoagulation, as stated by the Annals of the Rheumatic Diseases 6
- In cases where both inflammatory and thrombotic mechanisms coexist, combination of immunosuppressive and anticoagulant therapy may be considered, according to the Annals of the Rheumatic Diseases 6
- For SLE patients with persistently positive, moderate-to-high titers of antiphospholipid antibodies but without thrombotic events, antiplatelet agents may be considered for primary prevention, as recommended by the European League Against Rheumatism 1, 5